Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Pancreatic Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
25 drugs · 152 active trials
4 drugs · 116 active trials
8 drugs · 223 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 19 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Topotecan | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Oct 20, 2021 |
| Decitabine | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | 2016-03 |
| Enzalutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | May 22, 2014 |
| Alpelisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Oct 30, 2014 |
| Buparlisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2012-05 |
| Fulvestrant | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Jan 23, 2020 |
| Icotinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2013-12 |
| Imatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-07 |
| Retifanlimab | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | Feb 3, 2021 |
| Talimogene Laherparepvec | Phase 1 | Phase 1 | 0 | 0 | 0 | 2 | 0 | — | — | 2006-11 |
| 2-Deoxy-D-glucose | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-02 |
| Abiraterone | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Alectinib | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 30, 2023 |
| Alisertib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 9, 2013 |
| Anastrozole | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 30, 2023 |
| Bendamustine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 14, 2021 |
| Bicalutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Birabresib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 23, 2014 |
| Bleomycin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2000-12 |
| Cabazitaxel | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Calaspargase Pegol | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 9, 2022 |
| Chloroquine | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-07 |
| Darolutamide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Dinaciclib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 15, 2013 |
| Enasidenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| FOLFOX-6 Regimen | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 17, 2011 |
| Idelalisib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Lorlatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Molibresib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 18, 2020 |
| Motesanib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2004-12 |
| Nogapendekin Alfa Inbakicept | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 1, 2026 |
| Pegargiminase | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 17, 2014 |
| Pegfilgrastim | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 5, 2016 |
| Pexidartinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2016-06 |
| Picoplatin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2007-04 |
| Ponatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Porcupine Inhibitor WNT974 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 1, 2011 |
| Tofacitinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 29, 2019 |
| Tovorafenib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 2, 2022 |
| Venetoclax | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 1, 2020 |
| Vociprotafib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 31, 2022 |
| Bazedoxifene | Phase not stated | N/A | 0 | 0 | 0 | 1 | 0 | — | — | Feb 1, 2022 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.